Home › Crohn's Disease › Connecticut
Crohn's Disease clinical trials in Connecticut
14 studies for Crohn's Disease are looking for participants at sites in Connecticut.
Cities in Connecticut
Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
- Connecticut Clinical Research Institute ( Site 0297), Bristol
RecruitingPhase 3
All ages · All sexes · Updated Oct 2, 2026 · NCT06651281A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
- Yale University School of Medicine-Digestive Disease ( Site 5019), New Haven
RecruitingPhase 3
Ages 16 to 80 · All sexes · Updated Oct 2, 2026 · NCT06430801Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
- Danbury Hospital, Western Connecticut Health Network /ID# 265556, Danbury
- Yale University School of Medicine /ID# 266786, New Haven
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Sep 25, 2026 · NCT06548542A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
- Medical Research Center of Connecticut, Hamden
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07499232Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- Smilow Cancer Center/Yale-New Haven Hospital, New Haven
- Yale University, New Haven
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT03816345An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- Yale University Digestive Disease-Site Number: 8400108, New Haven
RecruitingPhase 3
Ages 16 to 80 · All sexes · Updated Sep 23, 2026 · NCT07184931A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
- Connecticut Children's Medical Center, Hartford
RecruitingPhase 3
Ages 2 to 19 · All sexes · Updated Sep 22, 2026 · NCT04844606A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
- Medical Research Center of Connecticut, LLC, Hamden
RecruitingPhase 4
Ages 18 to 70 · All sexes · Updated Sep 9, 2026 · NCT06045754A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
- Connecticut Children's Medical Center, Hartford
RecruitingPhase 3
Ages 2 to 17 · All sexes · Updated Aug 24, 2026 · NCT05509777Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission
- Yale University, New Haven
Recruiting
Ages 18 and older · All sexes · Updated Aug 7, 2026 · NCT05230173Zymfentra (Infliximab-dyyb) REal World Cohort STudy
- Yale University School of Medicine, New Haven
RecruitingObservational study
Ages 18 and older · All sexes · Updated Aug 5, 2026 · NCT07237516Assessment and Educational Intervention to Reduce Ultra-processed Food Consumption in Pediatric Patients With IBD
- Connecticut Children's Medical Center, Hartford
RecruitingObservational studyHealthy volunteers welcome
Ages 10 to 21 · All sexes · Updated Jul 16, 2026 · NCT07224113Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
- Connecticut Children's Medical Center - Hartford /ID# 262256, Hartford
RecruitingPhase 3
Ages 2 to 17 · All sexes · Updated Jun 24, 2026 · NCT06332534Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease
- Connecticut Children's Medical Center, Hartford
RecruitingPhase 4
Ages 6 to 17 · All sexes · Updated May 27, 2026 · NCT05781152From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.